mellitus. The major PDE5 inhibitors (a subset of the phosphodiesterase inhibitors) are sildenafil, tadalafil, vardenafil, and avanafil, and although all share...
42 KB (4,750 words) - 14:46, 13 July 2024
hypertension. As of 2019, the wider cardiovascular benefits of PDE5 inhibitors are being appreciated. Phosphodiesterase-5 (PDE5) inhibitors such as sildenafil...
16 KB (1,721 words) - 04:09, 24 May 2024
A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation...
22 KB (2,350 words) - 08:18, 3 June 2024
potential for selective phosphodiesterase inhibitors to be used as therapeutic agents was predicted in the 1970s by Weiss and coworkers. This prediction...
15 KB (1,725 words) - 08:12, 7 August 2024
A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4)...
18 KB (1,886 words) - 04:23, 15 August 2024
disorder (OCD), and migraine prevention. SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine...
78 KB (7,687 words) - 09:12, 6 April 2024
PDE1 (redirect from 5' nucleotide phosphodiesterase/alkaline phosphodiesterase I)
Phosphodiesterase 1, PDE1, EC 3.1.4.1, systematic name oligonucleotide 5′-nucleotidohydrolase) is a phosphodiesterase enzyme also known as calcium- and...
22 KB (2,564 words) - 01:35, 14 June 2024
Cereblon E3 ligase modulator (redirect from Discovery and development of thalidomide and its analogs)
TNF-α inhibitors such as rolipram and pentoxifylline did not inhibit myeloma cell growth nor angiogenesis. Upregulation of interferon gamma, IL-2 and IL-10...
49 KB (5,487 words) - 11:41, 24 January 2024
Sildenafil (category PDE5 inhibitors)
"Recreational use and misuse of phosphodiesterase 5 inhibitors". Journal of the American Pharmacists Association. 45 (1): 63–72, quiz 73–5. doi:10.1331/1544345052843165...
83 KB (7,403 words) - 17:16, 15 August 2024
the first JAK inhibitor, ruxolitinib, to treat a skin condition. Some JAK1 inhibitors are based on a benzimidazole core. JAK3 inhibitors target the catalytic...
36 KB (2,981 words) - 17:57, 23 June 2024